Patents by Inventor Rajesh Kumar Kainthan
Rajesh Kumar Kainthan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200331959Abstract: The present disclosure relates generally to methods of preparing glycoconjugates containing a saccharide conjugated to a carrier protein by use of stable nitroxyl radical related agent/oxidant as an oxidizing agent, to immunogenic compositions comprising such glycoconjugates, and to methods for the use of such glycoconjugates and immunogenic compositions.Type: ApplicationFiled: July 8, 2020Publication date: October 22, 2020Inventors: Mingming Han, Rajesh Kumar Kainthan, Jin-Hwan Kim, Avvari Krishna Prasad
-
Publication number: 20200306357Abstract: The present invention relates to new immunogenic compositions comprising conjughated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.Type: ApplicationFiled: June 12, 2020Publication date: October 1, 2020Inventors: Emilio Anthony Emini, Wendy Jo Watson, Avvari Krishna Prasad, Mingming Han, Jin-Hwan Kim, Jianxin Gu, Yu-ying Yang, Rajesh Kumar Kainthan, David Cooper, Michael William Pride, Kathrin Ute Jansen
-
Patent number: 10745438Abstract: The present disclosure relates generally to methods of preparing glycoconjugates containing a saccharide conjugated to a carrier protein by use of stable nitroxyl radical related agent/oxidant as an oxidizing agent, to immunogenic compositions comprising such glycoconjugates, and to methods for the use of such glycoconjugates and immunogenic compositions.Type: GrantFiled: July 9, 2019Date of Patent: August 18, 2020Assignee: Pfizer Inc.Inventors: Mingming Han, Rajesh Kumar Kainthan, Jin-Hwan Kim, Avvari Krishna Prasad
-
Publication number: 20200246475Abstract: The present invention relates generally to glycoconjugates comprising a saccharide covalently conjugated to a carrier protein through a spacer containing ((2-oxoethyl)thio)). In an aspect the invention provides oxo-eT linked glycoconjugates comprising a saccharide covalently conjugated to a carrier protein through a ((2-oxoethyl)thio) spacer having the formula (I): wherein: A is a group (C?X)m wherein X is S or O and m is 0 or 1; B is a bond, O, or CH2; and when m is 0, B can also be (C?O); R is a C2-C16 alkylene, C2-C16 heteroakylene, NH—C(?O)—C2-C16 alkylene, or NH—C(?O)—C2-C16 heteroakylene, wherein said alkylene and heteroalkylene are optionally substituted by 1, 2 or 3 groups independently selected from COOR? where R? is selected from H, methyl, ethyl or propyl. The invention further relates to immunogenic compositions comprising such glycoconjugates, and to methods for the preparation and use of such glycoconjugates and immunogenic compositions.Type: ApplicationFiled: April 20, 2020Publication date: August 6, 2020Inventors: Jianxin Gu, Rajesh Kumar Kainthan, Jin-Hwan Kim, Avvari Krishna Prasad, Yu-Ying Yang
-
Patent number: 10668164Abstract: The present invention relates generally to glycoconjugates comprising a saccharide covalently conjugated to a carrier protein through a spacer containing ((2-oxoethyl)thio)). In an aspect the invention provides oxo-eT linked glycoconjugates comprising a saccharide covalently conjugated to a carrier protein through a ((2-oxoethyl)thio) spacer having the formula (I): (I) wherein: A is a group (C?X)m wherein X is S or O and m is 0 or 1; B is a bond, O, or CH2; and when m is 0, B can also be (C?O); R is a C2-C16 alkylene, C2-C16 heteroalkylene, NH—C(?O)—C2-C16 alkylene, or NH—C(?O)—C2-C16 heteroalkylene, wherein said alkylene and heteroalkylene are optionally substituted by 1, 2 or 3 groups independently selected from COOR? where R? is selected from H, methyl, ethyl or propyl. The invention further relates to immunogenic compositions comprising such glycoconjugates, and to methods for the preparation and use of such glycoconjugates and immunogenic compositions.Type: GrantFiled: February 6, 2015Date of Patent: June 2, 2020Assignee: Pfizer Inc.Inventors: Jianxin Gu, Rajesh Kumar Kainthan, Jin-Hwan Kim, Avvari Krishna Prasad, Yu-Ying Yang
-
Patent number: 10525131Abstract: Herein are provided derivatized hyperbranched polyglycerols (“dHPGs”). The dHPG comprises a core comprising a hyperbranched polyglycerol derivatized with C1C20 alkyl chains and a shell comprising at least one hydrophilic substituent bound to hydroxyl groups of the core, wherein the hyperbranched polyglycerol comprises from about 1 to about 200 moles of the at least one hydrophilic substituent. The dHPGs are for use as agents for the delivery of a drug or other biologically active moiety to the urinary tract, the digestive tract, the airways, the vaginal cavity and cervix and the peritoneal cavity to treat indications such as cancer, which may be useful in the treatment of or the manufacture of a medicament, in the preparation, of a pharmaceutical composition for the treatment of cancer, as a pre-treatment or co-treatment to improve drug uptake in a tissue. Furthermore, there are provided methods of making dHPGs.Type: GrantFiled: July 26, 2018Date of Patent: January 7, 2020Assignees: The University of British Columbia, Centre for Drug Research and DevelopmentInventors: Helen M. Burt, Donald E. Brooks, Jayachandran N. Kizhakkedathu, Richard Liggins, Dechi Guan, Lu Ye, Clement Mugabe, Alan So, Martin E. Gleave, John K. Jackson, Rajesh Kumar Kainthan
-
Publication number: 20190330265Abstract: The present disclosure relates generally to methods of preparing glycoconjugates containing a saccharide conjugated to a carrier protein by use of stable nitroxyl radical related agent/oxidant as an oxidizing agent, to immunogenic compositions comprising such glycoconjugates, and to methods for the use of such glycoconjugates and immunogenic compositions.Type: ApplicationFiled: July 9, 2019Publication date: October 31, 2019Inventors: Mingming Han, Rajesh Kumar Kainthan, Jin-Hwan Kim, Avvari Krishna Prasad
-
Patent number: 10392420Abstract: The present disclosure relates generally to methods of preparing glycoconjugates containing a saccharide conjugated to a carrier protein by use of stable nitroxyl radical related agent/oxidant as an oxidizing agent, to immunogenic compositions comprising such glycoconjugates, and to methods for the use of such glycoconjugates and immunogenic compositions.Type: GrantFiled: December 13, 2013Date of Patent: August 27, 2019Assignee: Pfizer Inc.Inventors: Mingming Han, Rajesh Kumar Kainthan, Jin-Hwan Kim, Avvari Krishna Prasad
-
Publication number: 20190201528Abstract: Herein are provided derivatized hyperbranched polyglycerols (“dHPGs”). The dHPG comprises a core comprising a hyperbranched polyglycerol derivatized with C1C20 alkyl chains and a shell comprising at least one hydrophilic substituent bound to hydroxyl groups of the core, wherein the hyperbranched polyglycerol comprises from about 1 to about 200 moles of the at least one hydrophilic substituent. The dHPGs are for use as agents for the delivery of a drug or other biologically active moiety to the urinary tract, the digestive tract, the airways, the vaginal cavity and cervix and the peritoneal cavity to treat indications such as cancer, which may be useful in the treatment of or the manufacture of a medicament, in the preparation, of a pharmaceutical composition for the treatment of cancer, as a pre-treatment or co-treatment to improve drug uptake in a tissue. Furthermore, there are provided methods of making dHPGs.Type: ApplicationFiled: July 26, 2018Publication date: July 4, 2019Inventors: Helen M. Burt, Donald E. Brooks, Jayachandran N. Kizhakkedathu, Richard Liggins, Dechi Guan, Lu Ye, Clement Mugabe, Alan So, Martin E. Gleave, John K. Jackson, Rajesh Kumar Kainthan
-
Publication number: 20190142922Abstract: The invention relates to immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the CP has a sialic acid level of greater than about 60%. The invention also relates to methods of making the conjugates and immunogenic compositions comprising the conjugates. The invention also relates to immunogenic compositions comprising polysaccharide-protein conjugates, wherein the conjugates comprise a CP from GBS serotype IV and at least one additional serotype. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.Type: ApplicationFiled: January 11, 2019Publication date: May 16, 2019Inventors: Annaliesa Sybil Anderson, Amardeep Singh Bhupender Bhalla, Robert G.K. Donald, Jianxin Gu, Kathrin Ute Jansen, Rajesh Kumar Kainthan, Lakshmi Khandke, Jin-Hwan Kim, Paul Liberator, Avvari Krishna Prasad, Mark Edward Ruppen, Ingrid Lea Scully, Suddham Singh, Cindy Xudong Yang
-
Publication number: 20190091281Abstract: Pharmaceutical compositions having enhanced active component permeation properties are described.Type: ApplicationFiled: September 26, 2018Publication date: March 28, 2019Applicant: AQUESTIVE THERAPEUTICS, INC.Inventors: Stephen Paul Wargacki, Rajesh Kumar Kainthan, Alexander Mark Schobel
-
Patent number: 10226525Abstract: The invention relates to immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the CP has a sialic acid level of greater than about 60%. The invention also relates to methods of making the conjugates and immunogenic compositions comprising the conjugates. The invention also relates to immunogenic compositions comprising polysaccharide-protein conjugates, wherein the conjugates comprise a CP from GBS serotype IV and at least one additional serotype. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.Type: GrantFiled: May 3, 2016Date of Patent: March 12, 2019Assignee: Pfizer Inc.Inventors: Annaliesa Sybil Anderson, Amardeep Singh Bhupender Bhalla, Robert G. K. Donald, Jianxin Gu, Kathrin Ute Jansen, Rajesh Kumar Kainthan, Lakshmi Khandke, Jin-Hwan Kim, Paul Liberator, Avvari Krishna Prasad, Mark Edward Ruppen, Ingrid Lea Scully, Suddham Singh, Cindy Xudong Yang
-
Publication number: 20190000953Abstract: The invention relates to activated Streptococcus pneumoniae serotype 10A, 22F or 33F polysaccharides and processes for their preparation. The invention also relates to immunogenic conjugates comprising Streptococcus pneumoniae serotype 10A, 22F or 33F polysaccharides covalently linked to a carrier protein, processes for their preparation and immunogenic compositions and vaccines comprising them.Type: ApplicationFiled: September 17, 2018Publication date: January 3, 2019Inventors: Jianxin Gu, Rajesh Kumar Kainthan, Jin-Hwan Kim, Avvari Krishna Prasad, Yu-Ying Yang
-
Publication number: 20180369384Abstract: The present invention is based, in part, upon the discovery of charged lipids that provide advantages when used in lipid particles for the in vivo delivery of a therapeutic agent. As such, described herein are compounds useful for delivering a nucleic acid to a cell.Type: ApplicationFiled: May 16, 2017Publication date: December 27, 2018Applicant: Arbutus Biopharma CorporationInventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Muthusamy Jayaraman, David Butler, Mamta Kapoor, Rajesh Kumar Kainthan
-
Patent number: 10105431Abstract: The invention relates to activated Streptococcus pneumoniae serotype 10A, 22F or 33F polysaccharides and processes for their preparation. The invention also relates to immunogenic conjugates comprising Streptococcus pneumoniae serotype 10A, 22F or 33F polysaccharides covalently linked to a carrier protein, processes for their preparation and immunogenic compositions and vaccines comprising them.Type: GrantFiled: January 15, 2015Date of Patent: October 23, 2018Assignee: Pfizer Inc.Inventors: Jianxin Gu, Rajesh Kumar Kainthan, Jin-Hwan Kim, Avvari Krishna Prasad, Yu-Ying Yang
-
Patent number: 10071160Abstract: Herein are provided derivatized hyperbranched polyglycerols (“dHPGs”). The dHPG comprises a core comprising a hyperbranched polyglycerol derivatized with C1C20 alkyl chains and a shell comprising at least one hydrophilic substituent bound to hydroxyl groups of the core, wherein the hyperbranched polyglycerol comprises from about 1 to about 200 moles of the at least one hydrophilic substituent. The dHPGs are for use as agents for the delivery of a drug or other biologically active moiety to the urinary tract, the digestive tract, the airways, the vaginal cavity and cervix and the peritoneal cavity to treat indications such as cancer, which may be useful in the treatment of or the manufacture of a medicament, in the preparation, of a pharmaceutical composition for the treatment of cancer, as a pre-treatment or co-treatment to improve drug uptake in a tissue. Furthermore, there are provided methods of making dHPGs.Type: GrantFiled: December 22, 2016Date of Patent: September 11, 2018Assignees: The University of British Columbia, Centre for Drug Research and DevelopmentInventors: Helen M. Burt, Donald E. Brooks, Jayachandran N. Kizhakkedathu, Richard Liggins, Dechi Guan, Lu Ye, Clement Mugabe, Alan So, Martin E. Gleave, John K. Jackson, Rajesh Kumar Kainthan
-
Publication number: 20180099039Abstract: The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said novel immunogenic compositions.Type: ApplicationFiled: October 6, 2016Publication date: April 12, 2018Inventors: Emilio Anthony Emini, Wendy Jo Watson, Avvari Krishna Prasad, Mingming Han, Jin-Hwan Kim, Jianxin Gu, Yu-ying Yang, Rajesh Kumar Kainthan, David Cooper, Michael William Pride, Kathrin Ute Jansen
-
Publication number: 20170319696Abstract: Herein are provided derivatized hyperbranched polyglycerols (“dHPGs”). The dHPG comprises a core comprising a hyperbranched polyglycerol derivatized with C1C20 alkyl chains and a shell comprising at least one hydrophilic substituent bound to hydroxyl groups of the core, wherein the hyperbranched polyglycerol comprises from about 1 to about 200 moles of the at least one hydrophilic substituent. The dHPGs are for use as agents for the delivery of a drug or other biologically active moiety to the urinary tract, the digestive tract, the airways, the vaginal cavity and cervix and the peritoneal cavity to treat indications such as cancer, which may be useful in the treatment of or the manufacture of a medicament, in the preparation, of a pharmaceutical composition for the treatment of cancer, as a pre-treatment or co-treatment to improve drug uptake in a tissue. Furthermore, there are provided methods of making dHPGs.Type: ApplicationFiled: December 22, 2016Publication date: November 9, 2017Inventors: Helen M. Burt, Donald E. Brooks, Jayachandran N. Kizhakkedathu, Richard Liggins, Dechi Guan, Lu Ye, Clement Mugabe, Alan So, Martin E. Gleave, John K. Jackson, Rajesh Kumar Kainthan
-
Patent number: 9789056Abstract: This invention provides the use of a polymer comprising a hyperbranched polyether polyol such as hyperbranched polyglycerol as a serum albumin substitute. Also provided are high molecular weight hyperbranched polyglycerol polymers suitable for a variety of medical and non-medical uses including methods for making such high molecular weight polymers.Type: GrantFiled: April 18, 2016Date of Patent: October 17, 2017Assignee: The University of British ColumbiaInventors: Donald E. Brooks, Jayachandran N. Kizhakkedathu, Rajesh Kumar Kainthan
-
Patent number: 9687550Abstract: The present invention is based, in part, upon the discovery of charged lipids that provide advantages when used in lipid particles for the in vivo delivery of a therapeutic agent. As such, described herein are compounds useful for delivering a nucleic acid to a cell.Type: GrantFiled: December 7, 2010Date of Patent: June 27, 2017Assignee: Arbutus Biopharma CorporationInventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Muthusamy Jayaraman, David Butler, Mamta Kapoor, Rajesh Kumar Kainthan